mardi 29 janvier 2019

Onco Actu du 29 janvier 2019


1.4 BIOLOGIE - TECHNOS



3-D printing creates more realistic tumor models [Chemical and Engineering News]











2.6 ETIOLOGIE - ENVIRONNEMENT



U.S. judge to allow controversial evidence in Roundup cancer trials [Reuters]











3.4.1 CHIMIOPRÉVENTION - ASPIRINE



Aspirin and the treatment of cancer [The Guardian]











4. DÉPISTAGE, DIAGNOSTIC ET PRONOSTIC



Persistent sore throat 'can be cancer sign' [BBC News]










4.10 DÉP., DIAG. & PRONO. - FDA, EMA, NICE,...



Statement from FDA Commissioner Scott Gottlieb, M.D., and Jeff Shuren, M.D., Director of the Center for Devices and Radiological Health, on a record year for device innovation [FDA]











4.12 BIOPSIES LIQUIDES



Biocept Launches Liquid Biopsy Kits Intended to Broaden Use of its Proprietary Technology Platform for High Sensitivity Detection of Circulating Tumor DNA [Biocept]











5.12 IMMUNOTHÉRAPIES



Blocking pro-fibrosis signaling pathway may improve immunotherapy of metastatic breast cancer [Mass. General Hospital]











How the Body Fights Cancer and Intruders [Caltech]










5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES



Stand Up To Cancer Tackles T-Cell Lymphoma with Dream Team Focused on CAR-based Strategies Launched in Honor of Meg Vosburg [AACR]











5.12.5 IMMUNOTHÉRAPIES - PHARMA



Allogene Therapeutics, in Collaboration with Servier, Announces FDA Clearance of the IND for ALLO-501, an anti-CD19 Allogeneic CAR T (AlloCAR T™) Therapy [Allogene]











5.12.8 IMMUNOTHÉRAPIES - ECONOMIE



NICE Issues Recommendations for Axicabtagene Ciloleucel for Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma [ESMO]











5.2 PHARMA



Innate Pharma receives FDA fast track designation for IPH4102 in relapsed or refractory Sézary syndrome [Innate Pharma]











Zai Lab nabs speedy China regulatory review for PARP drug Zejula [EndPoints]











5.2.3 PHARMA - ÉCONOMIE



Amgen adds bone drug Xgeva to pharma's cancer-related lineup on TV [Fierce Pharma]











The next 5 years: Higher R&D productivity is here to stay, emerging biotechs and new tech will have a big impact. But what about pricing? [EndPoints]











5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)



Johnson & Johnson, AbbVie shore up Imbruvica's CLL lead with Gazyva combo win [Fierce Pharma]










With 10th FDA OK, Imbruvica further expands in CLL [Biopharma Dive]











Imbruvica regimen wins FDA approval as first non-chemotherapy treatment for untreated patients with common form of leukemia [EndPoints]











5.4 TRAITEMENTS - ECONOMIE



Health Affairs study misses the mark on medicine costs [PhRMA]











6.1 OBSERVATION



African American Men More Likely to Die from Low-Grade Prostate Cancer [NCI]










6.10 POLITIQUES



The impact of Brexit on the regulatory and marketing landscape [RAPS]











6.5 MÉDECINES ALTERNATIVES/COMPLÉMENTAIRES



Drs. Alberto Garcia and Alberto Siller’s Clínica 0-19: A mother’s story [Respectful Insolence]











6.7.1 IA/BIOINFORMATIQUE



The robot needs a human heart—why AI in medicine brings moral choices into focus [BMJ]











6.8 COMMUNICATION



Fighting misinformation on social media using crowdsourced judgments of news source quality [PNAS]